Wednesday, 24 June 2026 edition — The Vital Record
Vol. 1 · No. 22
Wednesday, 24 June 2026
“Evidence earns its keep or it doesn't.”
In this edition
Vol. 1, No. 22 leads with NIAID's STOMP trial confirming tecovirimat's futility for clade II mpox in the New England Journal of Medicine — a result that reshapes antiviral stockpiling calculus globally — alongside the FDA's June 22 complete response letter blocking cytisinicline, the first new smoking-cessation drug candidate in two decades, on manufacturing grounds alone.
Trials Today
Phase 3
STOMP (NCT05534984)
— Tecovirimat vs. placebo for clade II mpox; DSMB futility stop Nov 2024; primary endpoint not met (HR 0.98); NEJM Feb 2026
Phase 3
AURIGA (NCT03901963)
— Daratumumab-SC + lenalidomide vs. lenalidomide maintenance post-ASCT in MRD-positive NDMM; MRD-negative conversion 50.5% vs. 18.8%; trial completed June 4 2026
Phase 3
VALOR — Brepocitinib (PDUFA Q3 2026)
— Brepocitinib (TYK2/JAK1) vs. placebo in dermatomyositis; TIS +15.3 points (p<0.001); FDA Priority Review, decision expected within weeks
Phase 3
CORE/CORE2-TIMI 72 — Olezarsen (PDUFA June 30)
— Olezarsen vs. placebo in severe hypertriglyceridemia; TG reduction up to 72%; pancreatitis rate ratio 0.15; PDUFA date June 30 2026
Phase 3
THRIVE — Veligrotug (PDUFA June 30)
— Veligrotug (IGF-1R) vs. placebo in thyroid eye disease; proptosis responder rate 70% vs. ~5%; PDUFA date June 30 2026
Who's Who
Robert Michael
Chief Executive Officer, AbbVie
Announced AbbVie's $10.9 billion all-cash acquisition of Apogee Therapeutics on June 22, 2026, adding zumilokibart (APG777), an IL-13–targeting monoclonal antibody in late-stage development for atopic dermatitis and asthma, to AbbVie's immunology pipeline as it braces for Humira biosimilar headwinds.
The story →
The Daily Record
Medicine & biotech, fully cited, in your inbox each morning.
Free. Unsubscribe anytime.
← The archive